The Trump administration has committed to spend $1.95bn on 100m doses of a potential Covid-19 vaccine being developed by Germany’s BioNTech and US pharma giant Pfizer, which will be distributed free of charge to American citizens.
BioNTech announced on Wednesday that the supply agreement signed by the White House also includes the option for the US government to purchase a further 500m doses, subject to the vaccine being granted regulatory approval.
Several governments have signed agreements with some of the 24 groups currently testing a coronavirus vaccine on humans, including a promising candidate developed by Oxford university and AstraZeneca, but most other purchasers have refused to reveal the price paid per dose.
您已阅读21%（726字），剩余79%（2814字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。